In addition, we identify CAMK2D and CAMK2G as downstream effectors of PEAK1 in TNBC and ‘repurposing’ of the second generation CAMK2 inhibitor RA306 as a potential therapeutic strategy against oncogenic PEAK1 signalling in poor prognosis human cancers such as TNBC. Here, CAMK2G is linked to cancer.